快速通道FIT研究:疑似结直肠癌患者粪便免疫化学检测的诊断准确性
该研究纳入5040例符合NICE NG12疑似结直肠癌标准、由全科医生转诊的患者,在检查前完成粪便免疫化学检测(FIT)。结直肠癌检出率3.0%,FIT最佳截断值19 µg Hb/g粪便时灵敏度85.4%、特异度85.2%、阴性预测值99.5%。FIT有助于对NG12标准患者进行更个体化的结直肠癌风险评估和决策。
要点
- NG12疑似结直肠癌患者中FIT截断值19 µg Hb/g粪便时对结直肠癌灵敏度85.4%、特异度85.2%。
- 该截断值阴性预测值99.5%,阳性预测值15.1%。
- FIT可辅助NG12标准患者的个体化风险评估与后续检查决策。
核心结论
- 在符合NG12疑似结直肠癌标准的初级保健转诊患者中,FIT可用于更个体化的结直肠癌风险评估。
- FIT有助于以患者为中心决策后续检查的必要性、类型和时机。
研究设计与样本
- 前瞻性诊断准确性研究,纳入来自Yorkshire and Humber 12家二级诊疗机构、符合NG12疑似结直肠癌标准的初级保健转诊患者。
- 患者在研究检查前完成FIT,临床医生和患者对FIT结果设盲,基于最终诊断用ROC分析评估诊断准确性并确定统计最优截断值。
- 共5040例患者完成完整评估。
主要发现
- 5040例中检出结直肠癌151例(3.0%)。
- FIT对结直肠癌的最佳截断值为19 µg Hb/g粪便,灵敏度85.4%(95%CI 78.8%–90.6%),特异度85.2%(95%CI 84.1%–86.2%)。
- 该截断值下阴性预测值99.5%(95%CI 99.2%–99.7%),阳性预测值15.1%(95%CI 12.8%–17.7%)。
- 该截断值下对结直肠癌及显著癌前息肉的灵敏度62.9%(95%CI 57.5%–68.0%)、特异度86.4%(95%CI 85.4%–87.4%)。
- 该截断值下纳入所有器质性肠道疾病时灵敏度35.7%(95%CI 32.9%–38.5%)、特异度88.6%(95%CI 87.5%–89.6%)。
关键数值与推荐
- 研究采用ROC分析确定FIT统计最优截断值,以灵敏度和特异度最大化为基础。
- 结直肠癌最佳截断值为19 µg Hb/g粪便。
- 该截断值下结直肠癌灵敏度85.4%、特异度85.2%、阴性预测值99.5%、阳性预测值15.1%。
临床怎么用
- 对符合NG12疑似结直肠癌标准的初级保健转诊患者,可考虑在进一步检查前完成FIT以辅助风险评估。
- FIT结果可帮助全科医生与患者讨论后续检查的必要性、类型和时机。
- 解读FIT时应结合截断值19 µg Hb/g粪便对应的灵敏度、特异度和预测值。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The faecal immunochemical test (FIT) is now available to support clinicians in the assessment of patients at low risk of colorectal cancer (CRC) and within the bowel cancer screening programme. AIM: To determine the diagnostic accuracy of FIT for CRC and clinically significant disease in patients referred as they were judged by their GP to fulfil National Institute for Health and Care Excellence guideline 12 (NG12) criteria for suspected CRC. DESIGN AND SETTING: Patients referred from primary care with suspected CRC, meeting NG12 criteria, to 12 secondary care providers in Yorkshire and Humber were asked to complete a FIT before investigation. METHOD: The diagnostic accuracy of FIT based on final diagnosis was evaluated using receiver operating characteristics analysis. This permitted a statistically optimal cut-off value for FIT to be determined based on the maximisation of sensitivity and specificity. Clinicians and patients were blinded to the FIT results. RESULTS: In total, 5040 patients were fully evaluated and CRC was detected in 151 (3.0%). An optimal cut-off value of 19 µg Hb/g faeces for CRC was determined, giving a sensitivity of 85.4% (95% confidence interval [CI] = 78.8% to 90.6%) and specificity of 85.2% (95% CI = 84.1% to 86.2%). The negative predictive value at this cut-off value was 99.5% (95% CI = 99.2% to 99.7%) and the positive predictive value 15.1% (95% CI = 12.8% to 17.7%). Sensitivity and specificity of FIT for CRC and significant premalignant polyps at this cut-off value were 62.9% (95% CI = 57.5% to 68.0%) and 86.4% (95% CI = 85.4% to 87.4%), respectively; and when including all organic enteric disease were 35.7% (95% CI = 32.9% to 38.5%) and 88.6% (95% CI = 87.5% to 89.6%), respectively. CONCLUSION: FIT used in patients fulfilling NG12 criteria should allow for a more personalised CRC risk assessment. FIT should permit effective, patient-centred decision-making to inform the need for, type, and timing of further investigation.
引用
- Turvill JL, Turnock D, Cottingham D, et al. The Fast Track FIT study: diagnostic accuracy of faecal immunochemical test for haemoglobin in patients with suspected colorectal cancer. Br J Gen Pract. 2021. PMID: 33798091. doi:10.3399/BJGP.2020.1098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。